Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyPentoxifylline
Identification
- Name
- Pentoxifylline
- Accession Number
- DB00806 (APRD00121)
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Description
A methylxanthine derivative that inhibits phosphodiesterase and affects blood rheology. It improves blood flow by increasing erythrocyte and leukocyte flexibility. It also inhibits platelet aggregation. Pentoxifylline modulates immunologic activity by stimulating cytokine production. [PubChem]
- Structure
Structure for DB00806 (Pentoxifylline)
- Synonyms
- Oxpentifylline
- Pentoxifilina
- Pentoxifyllin
- Pentoxifylline
- Pentoxifyllinum
- External IDs
- BL 191 / BL-191 / C04AD03 / PTX
- Product Images
- Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Pentoxifylline SR Tablet, extended release 400 mg Oral Aa Pharma Inc 1997-01-14 Not applicable Canada 
Trental Tablet, extended release 400 mg Oral Sanofi Aventis 1996-10-23 2013-03-01 Canada Trental Srt 400mg Tablet, extended release 400 mg Oral Hoechst Roussel Canada Inc. 1993-12-31 1998-08-12 Canada Trental Tab 400mg Tablet, extended release 400 mg Oral Hoechst Canada Inc. 1984-12-31 1996-08-29 Canada - Generic Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Nu-pentoxifylline-SR 400 mg Tablet, extended release 400 mg Oral Nu Pharm Inc 1998-03-18 2012-09-04 Canada Pentoxifylline Tablet, extended release 400 mg/1 Oral Aidarex Pharmaceuticals LLC 1999-06-10 Not applicable US 
Pentoxifylline Tablet, extended release 400 mg/1 Oral Golden State Medical Supply 2001-06-18 Not applicable US Pentoxifylline Tablet, extended release 400 mg/1 Oral Physicians Total Care, Inc. 2003-03-25 Not applicable US 
Pentoxifylline Tablet, extended release 400 mg/1 Oral A S Medication Solutions 1998-07-31 2017-06-20 US Pentoxifylline Tablet, extended release 400 mg/1 Oral Teva 1998-07-31 Not applicable US Pentoxifylline Tablet, extended release 400 mg/1 Oral Nucare Pharmaceuticals, Inc. 1999-06-10 Not applicable US Pentoxifylline Tablet, film coated, extended release 400 mg/1 Oral State of Florida DOH Central Pharmacy 2009-07-01 Not applicable US Pentoxifylline Tablet, film coated, extended release 400 mg/1 Oral Ncs Health Care Of Ky, Inc Dba Vangard Labs 2009-09-21 Not applicable US Pentoxifylline Tablet, extended release 400 mg/1 Oral Lake Erie Medical Dba Quality Care Produts Llc 1998-07-31 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Gapeam Budibac Pentoxifylline + Amantadine hydrochloride + Baclofen + Bupivacaine hydrochloride + Cyclobenzaprine Hydrochloride + Diclofenac sodium + Gabapentin Kit Topical Alvix Laboratories 2014-12-05 2018-03-14 US - International/Other Brands
- Agapurin (Zentiva) / Agapurin SR (Zentiva) / An Ruo Ning (Nanjing Yaoda Bio-Pharmaceutical) / Angiopent (Helcor) / Ao Le Ni (C & O Pharmaceuticals) / Ao Nuo Hong (AosaiKang Pharmaceutical) / Aotong (Treeful Pharmaceutical) / Azupentat / Behrifil (Sanofi-Aventis) / Bo Shu Te (Jisheng Pharmaceutical) / Claudicat (Nycomed) / Durapental (Mylan dura) / Elorgan (Sanofi Aventis) / Endopentoksas (Endokriniai) / Pentilin (Krka) / Pentilin Retard (Krka) / Pentoflux (Bouchara-Recordati) / Pentofyllin (Sopharma) / Pentoksifilin (Panfarma) / Pentolab (Lamsa) / Pentomer (ratiopharm) / Pentoxil (Upsher-Smith) / Rentylin (Amdipharm) / Torental (Sanofi-Aventis) / Trental / Trentilin Retard (Santa-Farma)
- Categories
- Alkaloids
- Antioxidants
- Blood Viscosity Reducer
- Cardiovascular Agents
- Cardiovascular System
- Cytochrome P-450 CYP1A2 Inhibitors
- Cytochrome P-450 CYP1A2 Inhibitors (weak)
- Cytochrome P-450 CYP1A2 Substrates
- Cytochrome P-450 Enzyme Inhibitors
- Enzyme Inhibitors
- Free Radical Scavengers
- Hematologic Agents
- Hemorrheologic Agents
- Peripheral Vasodilators
- Phosphodiesterase Inhibitors
- Platelet Aggregation Inhibitors
- Protective Agents
- Purine Derivatives
- Purines
- Purinones
- Radiation-Protective Agents
- Theobromine
- Vasodilator Agents
- Xanthines
- UNII
- SD6QCT3TSU
- CAS number
- 6493-05-6
- Weight
- Average: 278.307
Monoisotopic: 278.137890462 - Chemical Formula
- C13H18N4O3
- InChI Key
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N
- InChI
- InChI=1S/C13H18N4O3/c1-9(18)6-4-5-7-17-12(19)10-11(14-8-15(10)2)16(3)13(17)20/h8H,4-7H2,1-3H3
- IUPAC Name
- 3,7-dimethyl-1-(5-oxohexyl)-2,3,6,7-tetrahydro-1H-purine-2,6-dione
- SMILES
- CN1C=NC2=C1C(=O)N(CCCCC(C)=O)C(=O)N2C
Pharmacology
- Indication
For the treatment of patients with intermittent lameness or immobility arising from chronic occlusive arterial disease of the limbs.
- Structured Indications
- Pharmacodynamics
Pentoxifylline, a synthetic dimethylxanthine derivative structurally related to theophylline and caffeine, is used in the treatment of peripheral vascular diseases and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.
- Mechanism of action
Pentoxifylline inhibits erythrocyte phosphodiesterase, resulting in an increase in erythrocyte cAMP activity. Subsequently, the erythrocyte membrane becomes more resistant to deformity. Along with erythrocyte activity, pentoxifylline also decreases blood viscosity by reducing plasma fibrinogen concentrations and increasing fibrinolytic activity. It is also a non selective adenosine receptor antagonist.
Target Actions Organism AcAMP-specific 3',5'-cyclic phosphodiesterase 4B inhibitorHuman AAdenosine receptor A1 antagonistHuman AcGMP-specific 3',5'-cyclic phosphodiesterase inhibitorHuman AcAMP-specific 3',5'-cyclic phosphodiesterase 4A inhibitorHuman AAdenosine receptor A2a antagonistHuman U5'-nucleotidase inhibitorHuman - Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
70%
- Metabolism
- Not Available
- Route of elimination
Excretion is almost totally urinary; the main biotransformation product is Metabolite V. Essentially no parent drug is found in the urine.
- Half life
0.4-0.8 hours
- Clearance
- Not Available
- Toxicity
LD50=1385 mg/kg(orally in mice)
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group Abciximab Pentoxifylline may increase the antiplatelet activities of Abciximab. Approved Abiraterone The serum concentration of Pentoxifylline can be increased when it is combined with Abiraterone. Approved Acebutolol Pentoxifylline may increase the hypotensive activities of Acebutolol. Approved, Investigational Acenocoumarol Pentoxifylline may increase the anticoagulant activities of Acenocoumarol. Approved, Investigational Acetylsalicylic acid Pentoxifylline may increase the antiplatelet activities of Acetylsalicylic acid. Approved, Vet Approved Aliskiren Pentoxifylline may increase the hypotensive activities of Aliskiren. Approved, Investigational Aloxiprin The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Aloxiprin. Experimental Alprenolol Pentoxifylline may increase the hypotensive activities of Alprenolol. Approved, Withdrawn Alprostadil Pentoxifylline may increase the antiplatelet activities of Alprostadil. Approved, Investigational Alteplase Pentoxifylline may increase the anticoagulant activities of Alteplase. Approved Ambrisentan Pentoxifylline may increase the hypotensive activities of Ambrisentan. Approved, Investigational Ambroxol acefyllinate The serum concentration of Ambroxol acefyllinate can be increased when it is combined with Pentoxifylline. Experimental, Investigational Aminophylline The serum concentration of Aminophylline can be increased when it is combined with Pentoxifylline. Approved Aminosalicylic Acid The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Aminosalicylic Acid. Approved Amlodipine Pentoxifylline may increase the hypotensive activities of Amlodipine. Approved Anagrelide Pentoxifylline may increase the antiplatelet activities of Anagrelide. Approved Ancrod Pentoxifylline may increase the anticoagulant activities of Ancrod. Approved, Investigational Andrographolide Pentoxifylline may increase the antiplatelet activities of Andrographolide. Investigational Anistreplase Pentoxifylline may increase the anticoagulant activities of Anistreplase. Approved Antithrombin III human Pentoxifylline may increase the anticoagulant activities of Antithrombin III human. Approved Apixaban The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Apixaban. Approved Ardeparin Pentoxifylline may increase the anticoagulant activities of Ardeparin. Approved, Investigational, Withdrawn Argatroban Pentoxifylline may increase the antiplatelet activities of Argatroban. Approved, Investigational Astaxanthin Pentoxifylline may increase the anticoagulant activities of Astaxanthin. Investigational Atenolol Pentoxifylline may increase the hypotensive activities of Atenolol. Approved Azelastine Pentoxifylline may increase the antiplatelet activities of Azelastine. Approved Azithromycin The metabolism of Pentoxifylline can be decreased when combined with Azithromycin. Approved Balsalazide The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Balsalazide. Approved, Investigational Batroxobin Pentoxifylline may increase the anticoagulant activities of Batroxobin. Experimental Becaplermin Pentoxifylline may increase the anticoagulant activities of Becaplermin. Approved, Investigational Bemiparin Pentoxifylline may increase the anticoagulant activities of Bemiparin. Approved, Investigational Benazepril Pentoxifylline may increase the hypotensive activities of Benazepril. Approved, Investigational Bendroflumethiazide Pentoxifylline may increase the hypotensive activities of Bendroflumethiazide. Approved Bepridil Pentoxifylline may increase the hypotensive activities of Bepridil. Approved, Withdrawn Beraprost Pentoxifylline may increase the antiplatelet activities of Beraprost. Investigational Betaxolol Pentoxifylline may increase the hypotensive activities of Betaxolol. Approved, Investigational Bethanidine Pentoxifylline may increase the hypotensive activities of Bethanidine. Approved Bietaserpine Pentoxifylline may increase the hypotensive activities of Bietaserpine. Experimental Bimatoprost Pentoxifylline may increase the hypotensive activities of Bimatoprost. Approved, Investigational Bisoprolol Pentoxifylline may increase the hypotensive activities of Bisoprolol. Approved Bivalirudin Pentoxifylline may increase the anticoagulant activities of Bivalirudin. Approved, Investigational Bortezomib The metabolism of Pentoxifylline can be decreased when combined with Bortezomib. Approved, Investigational Bosentan Pentoxifylline may increase the hypotensive activities of Bosentan. Approved, Investigational BQ-123 Pentoxifylline may increase the hypotensive activities of BQ-123. Investigational Bretylium Pentoxifylline may increase the hypotensive activities of Bretylium. Approved Brimonidine Pentoxifylline may increase the hypotensive activities of Brimonidine. Approved Brinase Pentoxifylline may increase the anticoagulant activities of Brinase. Experimental Buflomedil Pentoxifylline may increase the antiplatelet activities of Buflomedil. Experimental Bupranolol Pentoxifylline may increase the hypotensive activities of Bupranolol. Approved Butylphthalide Pentoxifylline may increase the antiplatelet activities of Butylphthalide. Investigational Cadralazine Pentoxifylline may increase the hypotensive activities of Cadralazine. Experimental Cafedrine Pentoxifylline may increase the hypotensive activities of Cafedrine. Investigational Caffeine The metabolism of Pentoxifylline can be decreased when combined with Caffeine. Approved Candesartan Pentoxifylline may increase the hypotensive activities of Candesartan. Experimental Candesartan cilexetil Pentoxifylline may increase the hypotensive activities of Candesartan cilexetil. Approved Candoxatril Pentoxifylline may increase the hypotensive activities of Candoxatril. Experimental Cangrelor Pentoxifylline may increase the antiplatelet activities of Cangrelor. Approved Caplacizumab Pentoxifylline may increase the anticoagulant activities of Caplacizumab. Investigational Captopril Pentoxifylline may increase the hypotensive activities of Captopril. Approved Carbaspirin calcium The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Carbaspirin calcium. Experimental, Investigational Carteolol Pentoxifylline may increase the hypotensive activities of Carteolol. Approved Carvedilol Pentoxifylline may increase the hypotensive activities of Carvedilol. Approved, Investigational Celiprolol Pentoxifylline may increase the hypotensive activities of Celiprolol. Approved, Investigational Certoparin Pentoxifylline may increase the anticoagulant activities of Certoparin. Approved, Investigational Chlorothiazide Pentoxifylline may increase the hypotensive activities of Chlorothiazide. Approved, Vet Approved Chlorthalidone Pentoxifylline may increase the hypotensive activities of Chlorthalidone. Approved Cicletanine Pentoxifylline may increase the hypotensive activities of Cicletanine. Investigational Cilazapril Pentoxifylline may increase the hypotensive activities of Cilazapril. Approved Cilostazol Pentoxifylline may increase the antiplatelet activities of Cilostazol. Approved, Investigational Cimetidine The serum concentration of Pentoxifylline can be increased when it is combined with Cimetidine. Approved, Investigational Citalopram The metabolism of Pentoxifylline can be decreased when combined with Citalopram. Approved Citric Acid Pentoxifylline may increase the anticoagulant activities of Citric Acid. Approved, Nutraceutical, Vet Approved Clonidine Pentoxifylline may increase the hypotensive activities of Clonidine. Approved Clopidogrel Pentoxifylline may increase the antiplatelet activities of Clopidogrel. Approved Cloranolol Pentoxifylline may increase the hypotensive activities of Cloranolol. Experimental Cloricromen Pentoxifylline may increase the antiplatelet activities of Cloricromen. Experimental Clorindione Pentoxifylline may increase the anticoagulant activities of Clorindione. Experimental Clotrimazole The metabolism of Pentoxifylline can be decreased when combined with Clotrimazole. Approved, Vet Approved Collagenase clostridium histolyticum The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Collagenase clostridium histolyticum. Approved, Investigational Cryptenamine Pentoxifylline may increase the hypotensive activities of Cryptenamine. Approved Cyclopenthiazide Pentoxifylline may increase the hypotensive activities of Cyclopenthiazide. Experimental Cyclothiazide Pentoxifylline may increase the hypotensive activities of Cyclothiazide. Approved Cyproterone acetate The serum concentration of Pentoxifylline can be decreased when it is combined with Cyproterone acetate. Approved, Investigational Dabigatran etexilate Pentoxifylline may increase the anticoagulant activities of Dabigatran etexilate. Approved Dalteparin Pentoxifylline may increase the anticoagulant activities of Dalteparin. Approved Danaparoid Pentoxifylline may increase the anticoagulant activities of Danaparoid. Approved, Withdrawn Darexaban Pentoxifylline may increase the anticoagulant activities of Darexaban. Investigational Dasatinib Dasatinib may increase the anticoagulant activities of Pentoxifylline. Approved, Investigational Debrisoquin Pentoxifylline may increase the hypotensive activities of Debrisoquin. Approved, Investigational Deferasirox The serum concentration of Pentoxifylline can be increased when it is combined with Deferasirox. Approved, Investigational Defibrotide Pentoxifylline may increase the antiplatelet activities of Defibrotide. Approved, Investigational Delapril Pentoxifylline may increase the hypotensive activities of Delapril. Experimental Deoxycholic Acid The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Deoxycholic Acid. Approved Dersalazine The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Dersalazine. Investigational Deserpidine Pentoxifylline may increase the hypotensive activities of Deserpidine. Approved Desirudin Pentoxifylline may increase the anticoagulant activities of Desirudin. Approved Desmoteplase Pentoxifylline may increase the anticoagulant activities of Desmoteplase. Investigational Dextran Pentoxifylline may increase the anticoagulant activities of Dextran. Approved, Investigational, Vet Approved Diazoxide Pentoxifylline may increase the hypotensive activities of Diazoxide. Approved Dicoumarol Pentoxifylline may increase the anticoagulant activities of Dicoumarol. Approved Diethylnorspermine Pentoxifylline may increase the hypotensive activities of Diethylnorspermine. Investigational Diflunisal The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Diflunisal. Approved, Investigational Dihydralazine Pentoxifylline may increase the hypotensive activities of Dihydralazine. Approved, Investigational Diltiazem Pentoxifylline may increase the hypotensive activities of Diltiazem. Approved, Investigational Diphenadione Pentoxifylline may increase the anticoagulant activities of Diphenadione. Experimental Dipyridamole Pentoxifylline may increase the antiplatelet activities of Dipyridamole. Approved Ditazole Pentoxifylline may increase the anticoagulant activities of Ditazole. Approved, Withdrawn Dorzolamide Pentoxifylline may increase the hypotensive activities of Dorzolamide. Approved Dosulepin The serum concentration of Pentoxifylline can be increased when it is combined with Dosulepin. Approved Doxazosin Pentoxifylline may increase the hypotensive activities of Doxazosin. Approved Drotrecogin alfa Pentoxifylline may increase the anticoagulant activities of Drotrecogin alfa. Approved, Investigational, Withdrawn Dyphylline The serum concentration of Dyphylline can be increased when it is combined with Pentoxifylline. Approved Edetic Acid Pentoxifylline may increase the anticoagulant activities of Edetic Acid. Approved, Vet Approved Edoxaban Pentoxifylline may increase the anticoagulant activities of Edoxaban. Approved Efonidipine Pentoxifylline may increase the hypotensive activities of Efonidipine. Approved, Investigational Enalapril Pentoxifylline may increase the hypotensive activities of Enalapril. Approved, Vet Approved Enalaprilat Pentoxifylline may increase the hypotensive activities of Enalaprilat. Approved Endralazine Pentoxifylline may increase the hypotensive activities of Endralazine. Experimental Enoxaparin Pentoxifylline may increase the anticoagulant activities of Enoxaparin. Approved Epanolol Pentoxifylline may increase the hypotensive activities of Epanolol. Experimental Epinastine Pentoxifylline may increase the antiplatelet activities of Epinastine. Approved, Investigational Eplivanserin Pentoxifylline may increase the antiplatelet activities of Eplivanserin. Investigational eplivanserine Pentoxifylline may increase the antiplatelet activities of eplivanserine. Investigational Epoprostenol Pentoxifylline may increase the antiplatelet activities of Epoprostenol. Approved Eprosartan Pentoxifylline may increase the hypotensive activities of Eprosartan. Approved Eptifibatide Pentoxifylline may increase the antiplatelet activities of Eptifibatide. Approved, Investigational Ethyl biscoumacetate Pentoxifylline may increase the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Felodipine Pentoxifylline may increase the hypotensive activities of Felodipine. Approved, Investigational Fenoldopam Pentoxifylline may increase the hypotensive activities of Fenoldopam. Approved Ferulic acid Pentoxifylline may increase the hypotensive activities of Ferulic acid. Experimental Fibrinolysin Pentoxifylline may increase the anticoagulant activities of Fibrinolysin. Investigational Fluindione Pentoxifylline may increase the anticoagulant activities of Fluindione. Approved, Investigational Fluvoxamine The serum concentration of Pentoxifylline can be increased when it is combined with Fluvoxamine. Approved, Investigational Fondaparinux Pentoxifylline may increase the anticoagulant activities of Fondaparinux. Approved, Investigational Fondaparinux sodium Pentoxifylline may increase the anticoagulant activities of Fondaparinux sodium. Approved, Investigational Fosinopril Pentoxifylline may increase the hypotensive activities of Fosinopril. Approved Gabexate Pentoxifylline may increase the anticoagulant activities of Gabexate. Investigational Glucosamine Glucosamine may increase the antiplatelet activities of Pentoxifylline. Approved, Investigational Guacetisal The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Guacetisal. Experimental Guanabenz Pentoxifylline may increase the hypotensive activities of Guanabenz. Approved, Investigational Guanadrel Pentoxifylline may increase the hypotensive activities of Guanadrel. Approved Guanazodine Pentoxifylline may increase the hypotensive activities of Guanazodine. Experimental Guanethidine Pentoxifylline may increase the hypotensive activities of Guanethidine. Approved Guanfacine Pentoxifylline may increase the hypotensive activities of Guanfacine. Approved, Investigational Guanoclor Pentoxifylline may increase the hypotensive activities of Guanoclor. Experimental Guanoxabenz Pentoxifylline may increase the hypotensive activities of Guanoxabenz. Experimental Guanoxan Pentoxifylline may increase the hypotensive activities of Guanoxan. Experimental Hemoglobin crosfumaril The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Hemoglobin crosfumaril. Experimental Heparin Pentoxifylline may increase the anticoagulant activities of Heparin. Approved, Investigational Hexamethonium Pentoxifylline may increase the hypotensive activities of Hexamethonium. Experimental Higenamine Pentoxifylline may increase the anticoagulant activities of Higenamine. Investigational Hydralazine Pentoxifylline may increase the hypotensive activities of Hydralazine. Approved Hydrochlorothiazide Pentoxifylline may increase the hypotensive activities of Hydrochlorothiazide. Approved, Vet Approved Hydroflumethiazide Pentoxifylline may increase the hypotensive activities of Hydroflumethiazide. Approved, Investigational Hydroxytyrosol Pentoxifylline may increase the antiplatelet activities of Hydroxytyrosol. Investigational Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Ibritumomab tiuxetan. Approved, Investigational Ibrutinib The risk or severity of adverse effects can be increased when Ibrutinib is combined with Pentoxifylline. Approved Ibudilast Pentoxifylline may increase the antiplatelet activities of Ibudilast. Approved, Investigational Icosapent ethyl Pentoxifylline may increase the antiplatelet activities of Icosapent ethyl. Approved, Investigational, Nutraceutical Idraparinux Pentoxifylline may increase the anticoagulant activities of Idraparinux. Investigational Ifenprodil Pentoxifylline may increase the antiplatelet activities of Ifenprodil. Approved, Investigational, Withdrawn Ifetroban Pentoxifylline may increase the antiplatelet activities of Ifetroban. Investigational Iloprost Pentoxifylline may increase the antiplatelet activities of Iloprost. Approved, Investigational Imidapril Pentoxifylline may increase the hypotensive activities of Imidapril. Investigational Indapamide Pentoxifylline may increase the hypotensive activities of Indapamide. Approved Indenolol Pentoxifylline may increase the hypotensive activities of Indenolol. Withdrawn Indobufen Pentoxifylline may increase the antiplatelet activities of Indobufen. Investigational Indoramin Pentoxifylline may increase the hypotensive activities of Indoramin. Withdrawn Irbesartan Pentoxifylline may increase the hypotensive activities of Irbesartan. Approved, Investigational Isradipine Pentoxifylline may increase the hypotensive activities of Isradipine. Approved, Investigational Ketanserin Pentoxifylline may increase the antiplatelet activities of Ketanserin. Investigational Ketorolac The risk or severity of adverse effects can be increased when Ketorolac is combined with Pentoxifylline. Approved Labetalol Pentoxifylline may increase the hypotensive activities of Labetalol. Approved Lacidipine Pentoxifylline may increase the hypotensive activities of Lacidipine. Approved, Investigational Latanoprost Pentoxifylline may increase the hypotensive activities of Latanoprost. Approved, Investigational Lepirudin Pentoxifylline may increase the anticoagulant activities of Lepirudin. Approved Lercanidipine Pentoxifylline may increase the hypotensive activities of Lercanidipine. Approved, Investigational Letaxaban Pentoxifylline may increase the anticoagulant activities of Letaxaban. Investigational Lidocaine The metabolism of Pentoxifylline can be decreased when combined with Lidocaine. Approved, Vet Approved Limaprost Limaprost may increase the antiplatelet activities of Pentoxifylline. Approved, Investigational Linsidomine Pentoxifylline may increase the antiplatelet activities of Linsidomine. Experimental Lisinopril Pentoxifylline may increase the hypotensive activities of Lisinopril. Approved, Investigational Lobeglitazone The metabolism of Pentoxifylline can be decreased when combined with Lobeglitazone. Approved, Investigational Lofexidine Pentoxifylline may increase the hypotensive activities of Lofexidine. Approved, Investigational Losartan Pentoxifylline may increase the hypotensive activities of Losartan. Approved Macitentan Pentoxifylline may increase the hypotensive activities of Macitentan. Approved Manidipine Pentoxifylline may increase the hypotensive activities of Manidipine. Approved, Investigational Mecamylamine Pentoxifylline may increase the hypotensive activities of Mecamylamine. Approved, Investigational Melagatran Pentoxifylline may increase the anticoagulant activities of Melagatran. Experimental Mesalazine The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Mesalazine. Approved Methoserpidine Pentoxifylline may increase the hypotensive activities of Methoserpidine. Experimental Methyl salicylate The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Methyl salicylate. Approved, Vet Approved Methyldopa Pentoxifylline may increase the hypotensive activities of Methyldopa. Approved Metipranolol Pentoxifylline may increase the hypotensive activities of Metipranolol. Approved Metolazone Pentoxifylline may increase the hypotensive activities of Metolazone. Approved Metoprolol Pentoxifylline may increase the hypotensive activities of Metoprolol. Approved, Investigational Metyrosine Pentoxifylline may increase the hypotensive activities of Metyrosine. Approved Mexiletine The serum concentration of Pentoxifylline can be increased when it is combined with Mexiletine. Approved, Investigational Mibefradil Pentoxifylline may increase the hypotensive activities of Mibefradil. Investigational, Withdrawn Midostaurin The serum concentration of Pentoxifylline can be increased when it is combined with Midostaurin. Approved, Investigational Milrinone Pentoxifylline may increase the antiplatelet activities of Milrinone. Approved Minoxidil Pentoxifylline may increase the hypotensive activities of Minoxidil. Approved, Investigational Moexipril Pentoxifylline may increase the hypotensive activities of Moexipril. Approved Moxonidine Pentoxifylline may increase the hypotensive activities of Moxonidine. Approved, Investigational Muzolimine Pentoxifylline may increase the hypotensive activities of Muzolimine. Experimental Nadolol Pentoxifylline may increase the hypotensive activities of Nadolol. Approved Nadroparin Pentoxifylline may increase the anticoagulant activities of Nadroparin. Approved, Investigational Nafamostat Pentoxifylline may increase the anticoagulant activities of Nafamostat. Approved, Investigational Naftopidil Pentoxifylline may increase the antiplatelet activities of Naftopidil. Investigational Nebivolol Pentoxifylline may increase the hypotensive activities of Nebivolol. Approved, Investigational Nevirapine The metabolism of Pentoxifylline can be decreased when combined with Nevirapine. Approved Nicardipine Pentoxifylline may increase the hypotensive activities of Nicardipine. Approved, Investigational Nicorandil Pentoxifylline may increase the hypotensive activities of Nicorandil. Approved, Investigational Niguldipine Pentoxifylline may increase the hypotensive activities of Niguldipine. Experimental Nilvadipine Pentoxifylline may increase the hypotensive activities of Nilvadipine. Approved, Investigational Nimesulide Pentoxifylline may increase the antiplatelet activities of Nimesulide. Approved, Investigational, Withdrawn Nimodipine Pentoxifylline may increase the hypotensive activities of Nimodipine. Approved, Investigational Nisoldipine Pentoxifylline may increase the hypotensive activities of Nisoldipine. Approved Nitrendipine Pentoxifylline may increase the hypotensive activities of Nitrendipine. Approved, Investigational Nitroaspirin Pentoxifylline may increase the antiplatelet activities of Nitroaspirin. Investigational Nitroprusside Pentoxifylline may increase the hypotensive activities of Nitroprusside. Approved, Investigational Obinutuzumab The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Obinutuzumab. Approved, Investigational Olmesartan Pentoxifylline may increase the hypotensive activities of Olmesartan. Approved, Investigational Olsalazine The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Olsalazine. Approved Omapatrilat Pentoxifylline may increase the hypotensive activities of Omapatrilat. Investigational Omega-3 fatty acids Omega-3 fatty acids may increase the antiplatelet activities of Pentoxifylline. Approved, Nutraceutical Osimertinib The serum concentration of Pentoxifylline can be decreased when it is combined with Osimertinib. Approved Otamixaban Pentoxifylline may increase the anticoagulant activities of Otamixaban. Investigational Oxprenolol Pentoxifylline may increase the hypotensive activities of Oxprenolol. Approved Ozagrel Pentoxifylline may increase the anticoagulant activities of Ozagrel. Investigational Pargyline Pentoxifylline may increase the hypotensive activities of Pargyline. Approved Parnaparin Pentoxifylline may increase the anticoagulant activities of Parnaparin. Approved, Investigational Peginterferon alfa-2b The serum concentration of Pentoxifylline can be increased when it is combined with Peginterferon alfa-2b. Approved Penbutolol Pentoxifylline may increase the hypotensive activities of Penbutolol. Approved, Investigational Pentaerythritol Tetranitrate Pentoxifylline may increase the anticoagulant activities of Pentaerythritol Tetranitrate. Approved Pentolinium Pentoxifylline may increase the hypotensive activities of Pentolinium. Approved Pentosan Polysulfate The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Pentoxifylline. Approved Perindopril Pentoxifylline may increase the hypotensive activities of Perindopril. Approved Phenindione Pentoxifylline may increase the anticoagulant activities of Phenindione. Approved, Investigational Phenoxybenzamine Pentoxifylline may increase the hypotensive activities of Phenoxybenzamine. Approved Phenprocoumon Pentoxifylline may increase the anticoagulant activities of Phenprocoumon. Approved, Investigational Phentolamine Pentoxifylline may increase the hypotensive activities of Phentolamine. Approved Phenyl aminosalicylate The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Phenyl aminosalicylate. Approved Picotamide Pentoxifylline may increase the antiplatelet activities of Picotamide. Experimental Pinacidil Pentoxifylline may increase the hypotensive activities of Pinacidil. Approved Pindolol Pentoxifylline may increase the hypotensive activities of Pindolol. Approved, Investigational Platelet Activating Factor Pentoxifylline may increase the hypotensive activities of Platelet Activating Factor. Experimental Polythiazide Pentoxifylline may increase the hypotensive activities of Polythiazide. Approved Prasugrel Pentoxifylline may increase the antiplatelet activities of Prasugrel. Approved Prazosin Pentoxifylline may increase the hypotensive activities of Prazosin. Approved Propranolol Pentoxifylline may increase the hypotensive activities of Propranolol. Approved, Investigational Protein C Pentoxifylline may increase the anticoagulant activities of Protein C. Approved Protein S human Pentoxifylline may increase the anticoagulant activities of Protein S human. Approved Protocatechualdehyde Pentoxifylline may increase the anticoagulant activities of Protocatechualdehyde. Approved Quinapril Pentoxifylline may increase the hypotensive activities of Quinapril. Approved, Investigational Ramatroban Pentoxifylline may increase the antiplatelet activities of Ramatroban. Investigational Ramipril Pentoxifylline may increase the hypotensive activities of Ramipril. Approved Relcovaptan Pentoxifylline may increase the antiplatelet activities of Relcovaptan. Investigational Remikiren Pentoxifylline may increase the hypotensive activities of Remikiren. Approved Rescinnamine Pentoxifylline may increase the hypotensive activities of Rescinnamine. Approved Reserpine Pentoxifylline may increase the hypotensive activities of Reserpine. Approved, Investigational Resveratrol Pentoxifylline may increase the antiplatelet activities of Resveratrol. Approved, Experimental, Investigational Reteplase Pentoxifylline may increase the anticoagulant activities of Reteplase. Approved, Investigational Reviparin Pentoxifylline may increase the anticoagulant activities of Reviparin. Approved, Investigational Ridogrel Pentoxifylline may increase the antiplatelet activities of Ridogrel. Approved Rilmenidine Pentoxifylline may increase the hypotensive activities of Rilmenidine. Approved, Investigational Riociguat Pentoxifylline may increase the hypotensive activities of Riociguat. Approved Rivaroxaban Pentoxifylline may increase the anticoagulant activities of Rivaroxaban. Approved Ropinirole The metabolism of Pentoxifylline can be decreased when combined with Ropinirole. Approved, Investigational Rosiglitazone Pentoxifylline may increase the anticoagulant activities of Rosiglitazone. Approved, Investigational Rucaparib The metabolism of Pentoxifylline can be decreased when combined with Rucaparib. Approved, Investigational Salicylic acid The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Salicylic acid. Approved, Investigational, Vet Approved Saprisartan Pentoxifylline may increase the hypotensive activities of Saprisartan. Experimental Sarpogrelate Pentoxifylline may increase the antiplatelet activities of Sarpogrelate. Investigational Saruplase Pentoxifylline may increase the anticoagulant activities of Saruplase. Experimental Selexipag Pentoxifylline may increase the hypotensive activities of Selexipag. Approved Sevoflurane Pentoxifylline may increase the antiplatelet activities of Sevoflurane. Approved, Vet Approved Simeprevir The metabolism of Pentoxifylline can be decreased when combined with Simeprevir. Approved Sitaxentan Pentoxifylline may increase the hypotensive activities of Sitaxentan. Approved, Investigational, Withdrawn Spirapril Pentoxifylline may increase the hypotensive activities of Spirapril. Approved SRT501 Pentoxifylline may increase the antiplatelet activities of SRT501. Investigational Streptokinase Pentoxifylline may increase the anticoagulant activities of Streptokinase. Approved, Investigational Sulodexide Pentoxifylline may increase the anticoagulant activities of Sulodexide. Approved, Investigational Talinolol Pentoxifylline may increase the hypotensive activities of Talinolol. Investigational Telmisartan Pentoxifylline may increase the hypotensive activities of Telmisartan. Approved, Investigational Temocapril Pentoxifylline may increase the hypotensive activities of Temocapril. Experimental, Investigational Tenecteplase Pentoxifylline may increase the anticoagulant activities of Tenecteplase. Approved Tenofovir disoproxil The metabolism of Pentoxifylline can be decreased when combined with Tenofovir disoproxil. Approved, Investigational Teriflunomide The serum concentration of Pentoxifylline can be decreased when it is combined with Teriflunomide. Approved Terlipressin Pentoxifylline may increase the hypotensive activities of Terlipressin. Approved, Investigational Tesmilifene Pentoxifylline may increase the antiplatelet activities of Tesmilifene. Investigational Tetrahydropalmatine Pentoxifylline may increase the hypotensive activities of Tetrahydropalmatine. Investigational Theodrenaline Pentoxifylline may increase the hypotensive activities of Theodrenaline. Investigational Theophylline The serum concentration of Theophylline can be increased when it is combined with Pentoxifylline. Approved Tibolone Pentoxifylline may increase the hypotensive activities of Tibolone. Approved, Investigational Ticagrelor Pentoxifylline may increase the antiplatelet activities of Ticagrelor. Approved Ticlopidine Pentoxifylline may increase the antiplatelet activities of Ticlopidine. Approved Ticrynafen Pentoxifylline may increase the hypotensive activities of Ticrynafen. Withdrawn Timolol Pentoxifylline may increase the hypotensive activities of Timolol. Approved Tinzaparin Pentoxifylline may increase the anticoagulant activities of Tinzaparin. Approved Tioclomarol Pentoxifylline may increase the anticoagulant activities of Tioclomarol. Experimental Tipranavir Tipranavir may increase the antiplatelet activities of Pentoxifylline. Approved, Investigational Tirofiban Pentoxifylline may increase the antiplatelet activities of Tirofiban. Approved Tizanidine The serum concentration of Tizanidine can be increased when it is combined with Pentoxifylline. Approved, Investigational Tolazoline Pentoxifylline may increase the hypotensive activities of Tolazoline. Approved, Vet Approved Tolonidine Pentoxifylline may increase the hypotensive activities of Tolonidine. Experimental Torasemide Pentoxifylline may increase the hypotensive activities of Torasemide. Approved Tositumomab The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Tositumomab. Approved, Investigational Trandolapril Pentoxifylline may increase the hypotensive activities of Trandolapril. Approved Tranilast Pentoxifylline may increase the antiplatelet activities of Tranilast. Approved, Investigational Trapidil Pentoxifylline may increase the antiplatelet activities of Trapidil. Approved Travoprost Pentoxifylline may increase the hypotensive activities of Travoprost. Approved Treprostinil Pentoxifylline may increase the hypotensive activities of Treprostinil. Approved, Investigational Trichlormethiazide Pentoxifylline may increase the hypotensive activities of Trichlormethiazide. Approved, Vet Approved Triflusal Pentoxifylline may increase the antiplatelet activities of Triflusal. Approved, Investigational Trimazosin Pentoxifylline may increase the hypotensive activities of Trimazosin. Experimental Trimethaphan Pentoxifylline may increase the hypotensive activities of Trimethaphan. Approved, Investigational Trolamine salicylate The risk or severity of adverse effects can be increased when Pentoxifylline is combined with Trolamine salicylate. Approved Troxerutin Pentoxifylline may increase the anticoagulant activities of Troxerutin. Investigational Unoprostone Pentoxifylline may increase the hypotensive activities of Unoprostone. Approved, Investigational Urapidil Pentoxifylline may increase the hypotensive activities of Urapidil. Investigational Urokinase Pentoxifylline may increase the anticoagulant activities of Urokinase. Approved, Investigational, Withdrawn Valsartan Pentoxifylline may increase the hypotensive activities of Valsartan. Approved, Investigational Vemurafenib The serum concentration of Pentoxifylline can be increased when it is combined with Vemurafenib. Approved Vincamine Pentoxifylline may increase the hypotensive activities of Vincamine. Experimental Vinpocetine Pentoxifylline may increase the hypotensive activities of Vinpocetine. Investigational Vitamin E Vitamin E may increase the antiplatelet activities of Pentoxifylline. Approved, Nutraceutical, Vet Approved Vorapaxar Pentoxifylline may increase the antiplatelet activities of Vorapaxar. Approved Warfarin Pentoxifylline may increase the anticoagulant activities of Warfarin. Approved Ximelagatran Pentoxifylline may increase the anticoagulant activities of Ximelagatran. Approved, Investigational, Withdrawn Xipamide Pentoxifylline may increase the hypotensive activities of Xipamide. Experimental Xylometazoline Pentoxifylline may increase the hypotensive activities of Xylometazoline. Approved, Investigational Zofenopril Pentoxifylline may increase the hypotensive activities of Zofenopril. Experimental Zucapsaicin The metabolism of Pentoxifylline can be decreased when combined with Zucapsaicin. Approved, Investigational - Food Interactions
- Take with food to reduce irritation. Limit caffeine intake.
References
- General References
- Authors unspecified: European Pentoxifylline Multi-Infarct Dementia Study. Eur Neurol. 1996;36(5):315-21. [PubMed:8864715]
- External Links
- Human Metabolome Database
- HMDB0014944
- KEGG Drug
- D00501
- KEGG Compound
- C07424
- PubChem Compound
- 4740
- PubChem Substance
- 46505940
- ChemSpider
- 4578
- BindingDB
- 10850
- ChEBI
- 7986
- ChEMBL
- CHEMBL628
- Therapeutic Targets Database
- DAP000048
- PharmGKB
- PA450864
- HET
- PNX
- RxList
- RxList Drug Page
- Drugs.com
- Drugs.com Drug Page
- Wikipedia
- Pentoxifylline
- ATC Codes
- R03DA20 — Combinations of xanthines
- R03DA — Xanthines
- R03D — OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R03 — DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
- R — RESPIRATORY SYSTEM
- AHFS Codes
- 20:24.00 — Hemorrheologic Agents
- PDB Entries
- 2a3c / 3arr / 3aru / 3tvx
- FDA label
- Download (51.7 KB)
- MSDS
- Download (73.9 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Actavis elizabeth llc
- Apotex inc
- Biovail laboratories inc
- Heritage pharmaceuticals inc
- Impax laboratories inc
- Mylan pharmaceuticals inc
- Pliva inc
- Teva pharmaceuticals usa inc
- Watson laboratories inc
- Upsher smith laboratories inc
- Sanofi aventis us llc
- Packagers
- Amerisource Health Services Corp.
- Amneal Pharmaceuticals
- Apotex Inc.
- A-S Medication Solutions LLC
- Atlantic Biologicals Corporation
- Biovail Pharmaceuticals
- Cardinal Health
- Dept Health Central Pharmacy
- Dispensing Solutions
- Diversified Healthcare Services Inc.
- Gallipot
- Golden State Medical Supply Inc.
- Heartland Repack Services LLC
- Lake Erie Medical and Surgical Supply
- Major Pharmaceuticals
- Mckesson Corp.
- Merrell Pharmaceuticals Inc.
- Murfreesboro Pharmaceutical Nursing Supply
- Mylan
- Nucare Pharmaceuticals Inc.
- Pharmedix
- Physicians Total Care Inc.
- Pliva Inc.
- Prepak Systems Inc.
- Remedy Repack
- Sandhills Packaging Inc.
- Sanofi-Aventis Inc.
- Southwood Pharmaceuticals
- Teva Pharmaceutical Industries Ltd.
- Torpharm Inc.
- Tya Pharmaceuticals
- UDL Laboratories
- Upsher Smith Laboratories
- Va Cmop Dallas
- Vangard Labs Inc.
- Zoetica Pharmaceutical Corp.
- Dosage forms
Form Route Strength Kit Topical Tablet, extended release Oral 400 mg/1 Tablet, film coated, extended release Oral 400 mg/1 Tablet, extended release Oral 400 mg - Prices
Unit description Cost Unit TRENtal 400 mg Controlled Release Tabs 1.4USD tab Trental er 400 mg tablet 1.27USD tablet Pentoxifylline powder 0.91USD g Trental 400 mg Sustained-Release Tablet 0.88USD tablet Pentoxifylline 400 mg tablet sa 0.71USD tablet Pentoxifylline CR 400 mg Controlled Release Tabs 0.62USD tab Pentoxil 400 mg Controlled Release Tabs 0.62USD tab Pentoxil er 400 mg tablet 0.62USD tablet Pentoxifylline er 400 mg tablet 0.6USD tablet Apo-Pentoxifylline Sr 400 mg Sustained-Release Tablet 0.4USD tablet Nu-Pentoxifylline-Sr 400 mg Sustained-Release Tablet 0.4USD tablet DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 105 °C Not Available water solubility 7.7E+004 mg/L (at 25 °C) MERCK INDEX (1996) logP 0.29 BIOBYTE (1995) - Predicted Properties
Property Value Source Water Solubility 5.17 mg/mL ALOGPS logP 0.08 ALOGPS logP 0.23 ChemAxon logS -1.7 ALOGPS pKa (Strongest Acidic) 19.64 ChemAxon pKa (Strongest Basic) -0.93 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 75.51 Å2 ChemAxon Rotatable Bond Count 5 ChemAxon Refractivity 73.52 m3·mol-1 ChemAxon Polarizability 29.27 Å3 ChemAxon Number of Rings 2 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
Property Value Probability Human Intestinal Absorption + 1.0 Blood Brain Barrier + 0.9851 Caco-2 permeable - 0.5056 P-glycoprotein substrate Substrate 0.595 P-glycoprotein inhibitor I Non-inhibitor 0.6905 P-glycoprotein inhibitor II Inhibitor 0.7157 Renal organic cation transporter Non-inhibitor 0.7023 CYP450 2C9 substrate Non-substrate 0.7897 CYP450 2D6 substrate Non-substrate 0.9117 CYP450 3A4 substrate Substrate 0.6511 CYP450 1A2 substrate Inhibitor 0.9107 CYP450 2C9 inhibitor Non-inhibitor 0.9518 CYP450 2D6 inhibitor Non-inhibitor 0.943 CYP450 2C19 inhibitor Non-inhibitor 0.9313 CYP450 3A4 inhibitor Non-inhibitor 0.9827 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.901 Ames test Non AMES toxic 0.7131 Carcinogenicity Non-carcinogens 0.8965 Biodegradation Not ready biodegradable 0.7457 Rat acute toxicity 2.4070 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.6463 hERG inhibition (predictor II) Non-inhibitor 0.8734
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available LC-MS/MS Spectrum - LC-ESI-qTof , Positive LC-MS/MS Not Available MS/MS Spectrum - , positive LC-MS/MS splash10-0059-1890000000-c9be2fe26b2862cba4f5 MS/MS Spectrum - , positive LC-MS/MS splash10-001r-2900000000-d54457aaede5317cef72 LC-MS/MS Spectrum - LC-ESI-QFT , positive LC-MS/MS splash10-0059-2970000000-95d1edcd63b61b13b22e
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as xanthines. These are purine derivatives with a ketone group conjugated at carbons 2 and 6 of the purine moiety.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Imidazopyrimidines
- Sub Class
- Purines and purine derivatives
- Direct Parent
- Xanthines
- Alternative Parents
- 6-oxopurines / Alkaloids and derivatives / Pyrimidones / N-substituted imidazoles / Vinylogous amides / Heteroaromatic compounds / Ureas / Lactams / Ketones / Azacyclic compounds show 4 more
- Substituents
- Xanthine / 6-oxopurine / Purinone / Alkaloid or derivatives / Pyrimidone / N-substituted imidazole / Pyrimidine / Azole / Imidazole / Heteroaromatic compound show 14 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- oxopurine (CHEBI:7986)
Targets
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Metal ion binding
- Specific Function
- Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes. May be involved in mediating central nervous system effects of therapeutic agents ranging f...
- Gene Name
- PDE4B
- Uniprot ID
- Q07343
- Uniprot Name
- cAMP-specific 3',5'-cyclic phosphodiesterase 4B
- Molecular Weight
- 83342.695 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Purine nucleoside binding
- Specific Function
- Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibit adenylyl cyclase.
- Gene Name
- ADORA1
- Uniprot ID
- P30542
- Uniprot Name
- Adenosine receptor A1
- Molecular Weight
- 36511.325 Da
References
- Daly JW, Jacobson KA, Ukena D: Adenosine receptors: development of selective agonists and antagonists. Prog Clin Biol Res. 1987;230:41-63. [PubMed:3588607]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Metal ion binding
- Specific Function
- Plays a role in signal transduction by regulating the intracellular concentration of cyclic nucleotides. This phosphodiesterase catalyzes the specific hydrolysis of cGMP to 5'-GMP (PubMed:9714779, ...
- Gene Name
- PDE5A
- Uniprot ID
- O76074
- Uniprot Name
- cGMP-specific 3',5'-cyclic phosphodiesterase
- Molecular Weight
- 99984.14 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Inhibitor
- General Function
- Metal ion binding
- Specific Function
- Hydrolyzes the second messenger cAMP, which is a key regulator of many important physiological processes.
- Gene Name
- PDE4A
- Uniprot ID
- P27815
- Uniprot Name
- cAMP-specific 3',5'-cyclic phosphodiesterase 4A
- Molecular Weight
- 98142.155 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Identical protein binding
- Specific Function
- Receptor for adenosine. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase.
- Gene Name
- ADORA2A
- Uniprot ID
- P29274
- Uniprot Name
- Adenosine receptor A2a
- Molecular Weight
- 44706.925 Da
References
- Kreth S, Ledderose C, Luchting B, Weis F, Thiel M: Immunomodulatory properties of pentoxifylline are mediated via adenosine-dependent pathways. Shock. 2010 Jul;34(1):10-6. doi: 10.1097/SHK.0b013e3181cdc3e2. [PubMed:19997047]
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- Inhibitor
- General Function
- Nucleotide binding
- Specific Function
- Hydrolyzes extracellular nucleotides into membrane permeable nucleosides. Exhibits AMP-, NAD-, and NMN-nucleosidase activities.
- Gene Name
- NT5E
- Uniprot ID
- P21589
- Uniprot Name
- 5'-nucleotidase
- Molecular Weight
- 63367.255 Da
References
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
- Ustunsoy H, Sivrikoz MC, Tarakcioglu M, Bakir K, Guldur E, Celkan MA: The effects of pentoxifylline on the myocardial inflammation and ischemia-reperfusion injury during cardiopulmonary bypass. J Card Surg. 2006 Jan-Feb;21(1):57-61. [PubMed:16426349]
Enzymes
- Kind
- Protein
- Organism
- Human
- Pharmacological action
- Unknown
- Actions
- SubstrateInhibitor
- General Function
- Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
- Specific Function
- Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
- Gene Name
- CYP1A2
- Uniprot ID
- P05177
- Uniprot Name
- Cytochrome P450 1A2
- Molecular Weight
- 58293.76 Da
References
- Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Drug created on June 13, 2005 07:24 / Updated on April 23, 2018 23:03